Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 13/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019617 | 0.92 | PRF1 (0.50) | PRF1PDE4DLMNAGAAMAPT | |
| SCHEMBL2021232 | 0.83 | PRF1 (0.47) | PRF1PDE4DLMNAGAAMAPT | |
| SCHEMBL2018226 | 0.79 | PRF1 (0.51) | PRF1PDE4D | |
| SCHEMBL2017905 | 0.78 | PRF1 (0.52) | PRF1PDE4DLMNAGAAMAPT | |
| SCHEMBL2054407 | 0.76 | PRF1 (0.53) | PRF1LMNAGAAMAPTCYP3A4 | |
| SCHEMBL14761567 | 0.75 | PRF1 (0.50) | PRF1 | |
| SCHEMBL2044871 | 0.75 | PRF1 (0.45) | PRF1PDE4DLMNAGAAMAPT | |
| SCHEMBL14761142 | 0.75 | PRF1 (0.64) | PRF1LMNAGAAMAPT | |
| SCHEMBL14761558 | 0.75 | PRF1 (0.50) | PRF1PDE4DLMNAGAAMAPT | |
| SCHEMBL14761557 | 0.73 | PRF1 (0.50) | PRF1LMNAGAAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | PRF1 1/4885PDE4D 1037/4885LMNA 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.